Journal Article
. 2017 Jul;35(24).
doi: 10.1200/JCO.2017.74.0472.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Ian Krop 1 Nofisat Ismaila 1 Fabrice Andre 1 Robert C Bast 1 William Barlow 1 Deborah E Collyar 1 M Elizabeth Hammond 1 Nicole M Kuderer 1 Minetta C Liu 1 Robert G Mennel 1 Catherine Van Poznak 1 Antonio C Wolff 1 Vered Stearns 1 
Affiliations
  • PMID: 28692382
  •     15 References
  •     78 citations

Abstract

Purpose This focused update addresses the use of MammaPrint (Agendia, Irvine, CA) to guide decisions on the use of adjuvant systemic therapy. Methods ASCO uses a signals approach to facilitate guideline updates. For this focused update, the publication of the phase III randomized MINDACT (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy) study to evaluate the MammaPrint assay in 6,693 women with early-stage breast cancer provided a signal. An expert panel reviewed the results of the MINDACT study along with other published literature on the MammaPrint assay to assess for evidence of clinical utility. Recommendations If a patient has hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer, the MammaPrint assay may be used in those with high clinical risk to inform decisions on withholding adjuvant systemic chemotherapy due to its ability to identify a good-prognosis population with potentially limited chemotherapy benefit. Women in the low clinical risk category did not benefit from chemotherapy regardless of genomic MammaPrint risk group. Therefore, the MammaPrint assay does not have clinical utility in such patients. If a patient has hormone receptor-positive, HER2-negative, node-positive breast cancer, the MammaPrint assay may be used in patients with one to three positive nodes and a high clinical risk to inform decisions on withholding adjuvant systemic chemotherapy. However, such patients should be informed that a benefit from chemotherapy cannot be excluded, particularly in patients with greater than one involved lymph node. The clinician should not use the MammaPrint assay to guide decisions on adjuvant systemic therapy in patients with hormone receptor-positive, HER2-negative, node-positive breast cancer at low clinical risk, nor any patient with HER2-positive or triple-negative breast cancer, because of the lack of definitive data in these populations. Additional information can be found at www.asco.org/breast-cancer-guidelines and www.asco.org/guidelineswiki .

How quickly do systematic reviews go out of date? A survival analysis.
Kaveh G Shojania, Margaret Sampson, +3 authors, David Moher.
Ann Intern Med, 2007 Jul 20; 147(4). PMID: 17638714
Highly Cited.
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Stella Mook, Marjanka K Schmidt, +10 authors, TRANSBIG Consortium.
Breast Cancer Res Treat, 2008 Jul 29; 116(2). PMID: 18661261
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
Neelima Denduluri, Mark R Somerfield, +8 authors, Antonio C Wolff.
J Clin Oncol, 2016 Apr 20; 34(20). PMID: 27091714
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Long-term impact of the 70-gene signature on breast cancer outcome.
C A Drukker, H van Tinteren, +4 authors, L J Van't Veer.
Breast Cancer Res Treat, 2014 Jan 22; 143(3). PMID: 24445566    Free PMC article.
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
N Lynn Henry, Mark R Somerfield, +6 authors, Ian E Krop.
J Clin Oncol, 2016 Mar 24; 34(19). PMID: 27001586
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Validation of 70-gene prognosis signature in node-negative breast cancer.
J M Bueno-de-Mesquita, S C Linn, +16 authors, M J van de Vijver.
Breast Cancer Res Treat, 2008 Sep 27; 117(3). PMID: 18819002
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.
M Knauer, F Cardoso, +4 authors, L J van 't Veer.
Br J Cancer, 2010 Nov 18; 103(12). PMID: 21081926    Free PMC article.
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.
Michael Knauer, Stella Mook, +7 authors, Laura J van 't Veer.
Breast Cancer Res Treat, 2010 Mar 06; 120(3). PMID: 20204499
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
Carolyn D Runowicz, Corinne R Leach, +13 authors, Patricia A Ganz.
J Clin Oncol, 2015 Dec 09; 34(6). PMID: 26644543
Highly Cited. Systematic Review.
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
Laura J van 't Veer, Christina Yau, +6 authors, Linda Sofie Lindström.
Breast Cancer Res Treat, 2017 Aug 05; 166(2). PMID: 28776283    Free PMC article.
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Andrew Dodson, David Okonji, +6 authors, Mitch Dowsett.
Breast Cancer Res Treat, 2017 Nov 13; 168(1). PMID: 29128896    Free PMC article.
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2017 Dec 24; 20(7). PMID: 29273958    Free PMC article.
Review.
Luminal A Breast Cancer and Molecular Assays: A Review.
Jennifer J Gao, Sandra M Swain.
Oncologist, 2018 Feb 24; 23(5). PMID: 29472313    Free PMC article.
Review.
Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.
Onur Esbah, Berna Oksuzoglu.
Indian J Med Res, 2018 Mar 08; 146(5). PMID: 29512598    Free PMC article.
Review.
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
Irene E G van Hellemond, Sandra M E Geurts, Vivianne C G Tjan-Heijnen.
Curr Treat Options Oncol, 2018 Apr 29; 19(5). PMID: 29704066    Free PMC article.
Review.
High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients.
Pablo Mandó, Manglio Rizzo, +9 authors, Estrella Mariel Levy.
Onco Targets Ther, 2018 May 31; 11. PMID: 29844687    Free PMC article.
Prognostic gene expression assays in breast cancer: are two better than one?
Joseph A Sparano.
NPJ Breast Cancer, 2018 May 31; 4. PMID: 29845110    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2018 Jun 20; 20(8). PMID: 29916189    Free PMC article.
Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
Martin Sjöström, Johan Staaf, +6 authors, Irma Fredriksson.
Breast Cancer Res, 2018 Jul 06; 20(1). PMID: 29973242    Free PMC article.
Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Matthias Christgen, Stephan Bartels, +4 authors, Hans Kreipe.
Virchows Arch, 2018 Aug 11; 473(5). PMID: 30094493
Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer.
Fei Shan, Yu-Lin Liu, Qiang Wang, Yan-Long Shi.
Oncol Lett, 2018 Aug 22; 16(3). PMID: 30127925    Free PMC article.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Review.
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
André Filipe Vieira, Fernando Schmitt.
Front Med (Lausanne), 2018 Sep 21; 5. PMID: 30234119    Free PMC article.
Review.
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Yixiao Feng, Mia Spezia, +15 authors, Guosheng Ren.
Genes Dis, 2018 Sep 28; 5(2). PMID: 30258937    Free PMC article.
Highly Cited. Review.
An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
Giacomo Pelizzari, Grazia Arpino, +8 authors, Fabio Puglisi.
BMC Cancer, 2018 Sep 29; 18(1). PMID: 30261866    Free PMC article.
Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery?
Toralf Reimer, Jutta Engel, +3 authors, Oreste David Gentilini.
Breast Care (Basel), 2018 Dec 01; 13(5). PMID: 30498416    Free PMC article.
Review.
Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas.
Su-Min Ha, Shin Hwang, +10 authors, Sung-Gyu Lee.
Ann Surg Treat Res, 2018 Dec 07; 95(6). PMID: 30505821    Free PMC article.
Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases.
Wei-Rong Chen, Jia-Peng Deng, +3 authors, San-Gang Wu.
Cancer Res Treat, 2019 Mar 28; 51(4). PMID: 30913871    Free PMC article.
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Maria Vittoria Dieci, Valentina Guarneri, +16 authors, Veneto Oncology Network.
Oncologist, 2019 Jun 04; 24(11). PMID: 31152079    Free PMC article.
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Tanja Ovcaricek, Iztok Takac, Erika Matos.
Radiol Oncol, 2019 Sep 26; 53(3). PMID: 31553709    Free PMC article.
Review.
Impact of the 21-gene recurrence score assay on chemotherapy decision making and outcomes for breast cancer patients with four or more positive lymph nodes.
Qing-Hong Zhang, Wen-Wen Zhang, +4 authors, San-Gang Wu.
Ann Transl Med, 2019 Nov 09; 7(18). PMID: 31700882    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
Significant inter- and intra-laboratory variation in grading of invasive breast cancer: A nationwide study of 33,043 patients in the Netherlands.
Carmen van Dooijeweert, Paul J van Diest, +4 authors, Ivette A G Deckers.
Int J Cancer, 2019 Apr 13; 146(3). PMID: 30977119    Free PMC article.
AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer.
Jiehua He, Julia Y Tsang, +7 authors, Peng Sun.
BMC Cancer, 2020 Jan 08; 20(1). PMID: 31906874    Free PMC article.
Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Vanessa Petry, Renata Colombo Bonadio, +6 authors, Maria Del Pilar Estevez-Diz.
Fam Cancer, 2019 Nov 22; 19(1). PMID: 31748977
Review.
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
Malgorzata Banys-Paluchowski, Isabell Witzel, +11 authors, Volkmar Müller.
Sci Rep, 2019 Feb 21; 9(1). PMID: 30783124    Free PMC article.
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Joseph Sparano, Anne O'Neill, +5 authors, Kathy D Miller.
JAMA Oncol, 2018 Jul 29; 4(12). PMID: 30054636    Free PMC article.
Highly Cited.
Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Eric Liu, Scott Paulson, +6 authors, Lisa Bodei.
Oncologist, 2018 Aug 31; 24(6). PMID: 30158287    Free PMC article.
SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
Tarek M A Abdel-Fatah, Reuben J Broom, +20 authors, Dong-Xu Liu.
Br J Cancer, 2019 Mar 01; 120(7). PMID: 30816325    Free PMC article.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Valerie E Crolley, Husam Marashi, +12 authors, Judy King.
Breast Cancer Res Treat, 2020 Mar 15; 180(3). PMID: 32170635    Free PMC article.
Community education to enhance the more equitable use of precision medicine in Northern Manhattan.
Grace C Hillyer, Karen M Schmitt, +4 authors, Mary Beth Terry.
J Genet Couns, 2020 Mar 12; 29(2). PMID: 32157769    Free PMC article.
Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment.
Luka Dobovišek, Fran Krstanović, Simona Borštnar, Nataša Debeljak.
Cancers (Basel), 2020 Feb 29; 12(3). PMID: 32106399    Free PMC article.
Review.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease.
Gloria Assaker, Anne Camirand, +7 authors, Siham Sabri.
JNCI Cancer Spectr, 2020 Apr 17; 4(1). PMID: 32296756    Free PMC article.
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Ryan J O Dowling, Kevin Kalinsky, +29 authors, Pamela J Goodwin.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337479    Free PMC article.
Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma.
Teppei Sugano, Masayuki Yoshida, +7 authors, Tesshi Yamada.
Br J Cancer, 2020 Apr 09; 122(12). PMID: 32265507    Free PMC article.
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer.
K Almstedt, S Mendoza, +9 authors, M Schmidt.
Breast Cancer Res Treat, 2020 May 22; 182(1). PMID: 32436145    Free PMC article.
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.
Daniel A Goldstein, Chen Mayer, +5 authors, Hadar Goldvaser.
Cancer Med, 2020 May 07; 9(13). PMID: 32372569    Free PMC article.
Novel quantitative signature of tumor stromal architecture: polarized light imaging differentiates between myxoid and sclerotic human breast cancer stroma.
Blake Jones, Georgia Thomas, +3 authors, Mohammadali Khorasani.
Biomed Opt Express, 2020 Jul 09; 11(6). PMID: 32637252    Free PMC article.
The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review.
Sophie Gordon-Craig, Ruth M Parks, Kwok-Leung Cheung.
Oncol Ther, 2020 Jul 24; 8(2). PMID: 32700048    Free PMC article.
Review.
Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
Stephanie Robertson, Balazs Acs, Michael Lippert, Johan Hartman.
Breast Cancer Res Treat, 2020 Jun 24; 183(1). PMID: 32572716    Free PMC article.
Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
Rinat Bernstein-Molho, Bella Kaufman, +5 authors, Eitan Friedman.
Breast, 2019 Nov 25; 49. PMID: 31760168    Free PMC article.
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
Frédérique Penault-Llorca, Fabrice Kwiatkowski, +18 authors, Suzette Delaloge.
Breast, 2019 Dec 04; 49. PMID: 31790959    Free PMC article.
Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective.
Gouri Shankar Bhattacharyya, Dinesh C Doval, +3 authors, S P Somashekhar.
JCO Glob Oncol, 2020 Jun 09; 6. PMID: 32511068    Free PMC article.
Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial.
Laurent Jacob, Anke Witteveen, +17 authors, Annuska Glas.
Commun Biol, 2020 Jul 29; 3(1). PMID: 32719399    Free PMC article.
Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis.
Susanna M Wallerstedt, Astrid Nilsson Ek, +3 authors, Barbro Linderholm.
Eur J Clin Pharmacol, 2020 Jun 07; 76(9). PMID: 32504183    Free PMC article.
Review.
Prediction of nodal staging in breast cancer patients with 1-2 sentinel nodes in the Z0011 era.
Fabio Corsi, Luca Sorrentino, +4 authors, Marta Truffi.
Medicine (Baltimore), 2020 Sep 03; 99(35). PMID: 32871890    Free PMC article.
The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes.
Jun Wang, Zhen-Yu He, +3 authors, San-Gang Wu.
Front Genet, 2019 Jan 09; 9. PMID: 30619463    Free PMC article.
Cancer prevention and screening: the next step in the era of precision medicine.
Holli A Loomans-Kropp, Asad Umar.
NPJ Precis Oncol, 2019 Feb 01; 3. PMID: 30701196    Free PMC article.
Review.
Biomarker profiling for breast cancer detection: translational research to determine acceptance of a novel breast cancer screening technique.
Nick Carcioppolo, Katheryn R Christy, +3 authors, Daniel Raftery.
Health Syst (Basingstoke), 2018 Jan 04; 8(1). PMID: 31214353    Free PMC article.
Should a Multigene Signature be Used in all Luminal Early Breast Cancers.
Nawale Hajjaji, Yves Marie Robin, Jacques Bonneterre.
Front Oncol, 2019 Jun 20; 9. PMID: 31214499    Free PMC article.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Review.
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.
Tarek M A Abdel-Fatah, Reem Ali, +7 authors, Srinivasan Madhusudan.
Cancers (Basel), 2019 Aug 14; 11(8). PMID: 31405143    Free PMC article.
Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
Nora Pashayan, Antonis C Antoniou, +31 authors, Martin Widschwendter.
Nat Rev Clin Oncol, 2020 Jun 20; 17(11). PMID: 32555420    Free PMC article.
Review.
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Caterina Fumagalli, Alberto Ranghiero, +8 authors, Massimo Barberis.
Breast Cancer Res, 2020 Oct 17; 22(1). PMID: 33059724    Free PMC article.
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.
Jennifer Y Sheng, Cesar A Santa-Maria, +18 authors, Karen L Smith.
JCO Oncol Pract, 2020 Jul 01; 16(10). PMID: 32603252    Free PMC article.
Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines.
Lance Isidore Catedral, Harold Nathan Tan, +2 authors, Dennis L Sacdalan.
JCO Glob Oncol, 2020 Oct 21; 6. PMID: 33079606    Free PMC article.
How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects.
Sylwia Tabor, Małgorzata Szostakowska-Rodzos, Anna Fabisiewicz, Ewa A Grzybowska.
Int J Mol Sci, 2020 Nov 14; 21(21). PMID: 33182512    Free PMC article.
Review.
HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes.
Vic Hart, Hannah Gautrey, John Kirby, Alison Tyson-Capper.
Oncotarget, 2020 Nov 28; 11(46). PMID: 33245725    Free PMC article.
Review.
The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors.
Irvin M Modlin, Mark Kidd, +4 authors, Kyung-Min Chung.
Endocrinol Metab Clin North Am, 2018 Aug 14; 47(3). PMID: 30098712    Free PMC article.
Review.
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Hee Kyung Kim, Kyung Hee Park, +10 authors, Yeon Hee Park.
Cancer Res Treat, 2018 Sep 08; 51(2). PMID: 30189722    Free PMC article.
Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
Dinja T Kruger, Karin J Beelen, +4 authors, Sabine C Linn.
Br J Cancer, 2018 Oct 06; 119(7). PMID: 30287915    Free PMC article.
The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review.
C J H Kramer, K M H Vangangelt, +3 authors, W E Mesker.
Breast Cancer Res Treat, 2018 Oct 12; 173(1). PMID: 30302588    Free PMC article.
Review.
[Update of the German S3 breast cancer guideline : What is new for pathologists?]
A Lebeau, C Denkert, +2 authors, A Wöckel.
Pathologe, 2019 Mar 09; 40(2). PMID: 30847505
A 23 gene-based molecular prognostic score precisely predicts overall survival of breast cancer patients.
Hideyuki Shimizu, Keiichi I Nakayama.
EBioMedicine, 2019 Jul 31; 46. PMID: 31358476    Free PMC article.
Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Yutian Zou, Xiaoqian Hu, +5 authors, Xiaoming Xie.
EBioMedicine, 2020 Dec 15; 63. PMID: 33310681    Free PMC article.
The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer.
J E C van Steenhoven, A Kuijer, +5 authors, T van Dalen.
Ann Surg Oncol, 2019 Jun 19; 26(11). PMID: 31209664    Free PMC article.
Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer.
Laurence Slembrouck, Isabelle Vanden Bempt, +12 authors, Giuseppe Floris.
Mod Pathol, 2021 Feb 10;. PMID: 33558657
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Paolo Giorgi Rossi, Annette Lebeau, +13 authors, ECIBC Contributor Group.
Br J Cancer, 2021 Feb 19; 124(9). PMID: 33597715
Review.
A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.
Ainhoa Arana Echarri, Mark Beresford, +6 authors, James E Turner.
Front Immunol, 2021 Feb 19; 11. PMID: 33597950    Free PMC article.
Review.
Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer.
Della Makower, Juan Lin, Xiaonan Xue, Joseph A Sparano.
NPJ Breast Cancer, 2021 Mar 03; 7(1). PMID: 33649322    Free PMC article.
NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis.
Anna Malczewska, Kjell Oberg, Beata Kos-Kudla.
Endocr Connect, 2020 Dec 09; 10(1). PMID: 33289691    Free PMC article.
Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Maroun Bou Zerdan, Maryam Ibrahim, +2 authors, Hazem I Assi.
Front Oncol, 2021 Mar 06; 10. PMID: 33665165    Free PMC article.
Review.
Advanced Approaches to Breast Cancer Classification and Diagnosis.
M Zubair, S Wang, N Ali.
Front Pharmacol, 2021 Mar 16; 11. PMID: 33716731    Free PMC article.
Review.
GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature.
Patrizia Querzoli, Massimo Pedriali, +3 authors, Elisabetta Kuhn.
Diagnostics (Basel), 2021 Apr 04; 11(4). PMID: 33800667    Free PMC article.